The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...
The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...
New Brunswick, NJ January 21, 2025 Johnson & Johnson ( NYSE:JNJ) has finally got its breakthrough depression treatment, ...
The Food and Drug Administration has approved Johnson & Johnson's nasal spray as a standalone treatment for severe forms of ...
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...